Crown Bioscience and Turbine Partner on AI and Organoid Workflow in Oncology

Crown Bioscience and Turbine announced a strategic partnership on April 21 to integrate AI-driven biological prediction with experimental validation in translational oncology, according to a company release.

The collaboration connects Turbine’s in silico Virtual Assays with Crown Bioscience’s tumor organoid assays based on HUB Organoid Technology, creating a workflow that moves from hypothesis generation to validation in a single system. The companies said this approach is designed to improve predictive accuracy while reducing experimental burden.

Turbine’s platform simulates biological responses across thousands of samples and hundreds of drugs to identify and prioritize therapeutic targets and combinations. These predictions are combined with multimodal and drug response data from Crown Bioscience’s tumor organoid models, forming a closed-loop system that links computational output with experimental testing.

Connecting Prediction With Experimental Validation

Under the partnership, researchers can use Turbine’s simulations to narrow down candidate hypotheses before validating them in Crown Bioscience’s organoid assays. The companies said this structure enables more targeted experimental design, reduces costs, and shortens development timelines.